These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 14619248)

  • 1. Accounting for the missing opportunity costs in incremental cost-outcome analysis.
    Oliver A
    Appl Health Econ Health Policy; 2002; 1(4):191-6. PubMed ID: 14619248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life and health economics: where is the link?
    Jönsson B
    Scand J Gastroenterol Suppl; 1996; 221():33-6. PubMed ID: 9110396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Willingness to pay in the context of an economic evaluation of healthcare programs: theory and practice.
    Gafni A
    Am J Manag Care; 1997 May; 3 Suppl():S21-32. PubMed ID: 10180338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation using mathematical models: the case of misoprostol prophylaxis.
    Gabriel SE
    J Rheumatol; 1995 Jul; 22(7):1412-4. PubMed ID: 7562787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
    Pickard AS; Wang Z; Walton SM; Lee TA
    Health Qual Life Outcomes; 2005 Mar; 3():11. PubMed ID: 15748287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic evaluation of health care.
    Haas M; Hall J
    Health Inf Manag; 1998 Dec-1999 Feb; 28(4):169-72. PubMed ID: 10387363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in economic outcomes research.
    Cook JR
    Hepatology; 1999 Jun; 29(6 Suppl):23S-25S. PubMed ID: 10386079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technology.
    Banz K;
    Value Health; 2005; 8(2):128-39. PubMed ID: 15804321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
    Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
    Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic evaluation of targeted cancer therapy].
    Ikeda S
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):967-70. PubMed ID: 23986036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC; Brown MM; Turpcu A; Rajput Y
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness ratios: in a league of their own.
    Birch S; Gafni A
    Health Policy; 1994 May; 28(2):133-41. PubMed ID: 10136058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
    Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
    Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses.
    Angevine PD; Berven S
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S9-15. PubMed ID: 25299265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.